An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation

American Journal of Transplantation

Volumn 17, Issue 9, 2017, Pages 2468-2473

  Kumar, D ^a   Mian, M ^a   Singer, L ^a   Humar, A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

antibiotic: antiviral ganciclovir valganciclovir; clinical research practice; infection and infectious agents; infectious disease; viral: Cytomegalovirus (CMV)

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL OUTCOME; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION PREVENTION; INTERVENTION STUDY; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RECURRENT DISEASE; SAFETY; TRANSPLANTATION; TREATMENT DURATION; VIRUS LOAD; CYTOMEGALOVIRUS; EARLY INTERVENTION; FOLLOW UP; GENETICS; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; T LYMPHOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EARLY MEDICAL INTERVENTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PRECISION MEDICINE; PROGNOSIS; RISK FACTORS; T-LYMPHOCYTES; VIRAL LOAD;

EID: 85021407330     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14347     Document Type: Article

References (10)

1. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106–2113.
2. Natori Y, Humar A, Husain S, et al. Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients. Transplantation 2017; 101: 1449–1454.
3. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: A primer for the clinician. Clin Infect Dis 2012; 55: 1678–1689.
4. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 2013; 56: 817–824.
5. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 93: 195–200.
6. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214–1222.
7. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333–360.
8. Crough T, Khanna R. Immunobiology of human cytomegalovirus: From bench to bedside. Clin Microbiol Rev 2009; 22: 76–98, Table of Contents.
9. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673–685.
10. Sood S, Cundall D, Yu L, et al. A novel biomarker of immune function and initial experience in a transplant population. Transplantation 2014; 97: e50–e51.